Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech
Dr. Helén Tuvesson takes up the post as Chief Scientific Officer within Active
Biotech from April 1, 2011. Helén Tuvesson will be reporting to Tomas
Leanderson, President & CEO.
Dr. Tuvesson has worked in the pharmaceutical industry for more than 20 years
and has extensive experience in drug development, from the early preclinical
stage up to late clinical development. Helén has been on different positions
within Active Biotech since 1998, most recently as Head of the department of
Preclinical Development. She has been a member of the R&D management for three
years, and the recent year also in the senior management team at Active Biotech.
The appointment will strengthen Active Biotech's R&D capabilities going forward
after the recent positive results obtained in the laquinimod and TASQ clinical
Lund, March 15, 2011
Active Biotech AB (publ)
For further information, please contact:
Tel: +46 (0)46 19 20 95
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy, primarily of
renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 3:00 pm CET on March 15, 2011.
Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE